EVOTAZ

Drug E.R. Squibb & Sons, L.L.C.
Total Payments
$25,507
Transactions
217
Doctors
133
Companies
1

Payment Trends by Year

Year Amount Transactions Doctors
2022 $61.65 3 3
2019 $12.74 1 1
2017 $25,433 213 129

Payments by Nature

Nature of Payment Amount Transactions Share
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $11,928 6 46.8%
Consulting Fee $6,500 13 25.5%
Food and Beverage $5,972 187 23.4%
Travel and Lodging $1,107 11 4.3%

Top Doctors Receiving Payments for EVOTAZ — Page 6

Doctor Specialty Location Total Records
, DO Infectious Disease Southfield, MI $11.61 1
, MD Hematology & Oncology Southfield, MI $11.61 1
, MD Internal Medicine Athens, GA $11.61 1
, MD Family Medicine Columbia, MD $11.49 1
, MD Child & Adolescent Psychiatry Baltimore, MD $11.49 1
, MD Infectious Disease Baltimore, MD $11.49 1
, MD Family Medicine Fort Pierce, FL $11.16 1
, DO Hematology Ormond Beach, FL $10.50 1

About EVOTAZ

EVOTAZ is a drug associated with $25,507 in payments to 133 healthcare providers, recorded across 217 transactions in the CMS Open Payments database. The primary manufacturer is E.R. Squibb & Sons, L.L.C..

Payment data is available from 2017 to 2022. In 2022, $61.65 was paid across 3 transactions to 3 doctors.

The most common payment nature for EVOTAZ is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($11,928, 46.8% of total).